What Is VenaBlock®?
VenaBlock® is a next-generation non-thermal endovenous closure system developed for the treatment of chronic venous insufficiency and symptomatic varicose veins. Unlike traditional thermal ablation techniques — such as endovenous laser ablation (EVLA) or radiofrequency ablation (RFA) — VenaBlock® seals diseased veins using medical-grade cyanoacrylate adhesive, completely eliminating the need for heat energy.
The Technology Behind VenaBlock®
The active ingredient in VenaBlock® is a specifically formulated cyanoacrylate polymer — a class of medical-grade adhesive widely used in surgical applications. When introduced into the lumen of an incompetent saphenous vein, the adhesive rapidly polymerizes on contact with blood, creating a durable mechanical seal that permanently closes the vein.
The procedure is performed under real-time duplex ultrasound guidance, ensuring precise catheter positioning and controlled adhesive delivery throughout the vein segment.
Key Clinical Advantages
- No thermal energy: Eliminates the risk of nerve damage and skin burns associated with laser and RF techniques
- No tumescent anesthesia: Only a single injection at the puncture site — significantly reducing patient discomfort
- Reduced adhesive volume: ~1.2 ml per vein, up to 30% less than comparable systems
- Rapid recovery: Most patients resume normal activities within 2 hours
- Compression stockings optional: No mandatory post-procedure compression requirement
Who Is VenaBlock® Indicated For?
VenaBlock® is indicated for patients with symptomatic great saphenous vein (GSV) or small saphenous vein (SSV) incompetence, classified CEAP C2–C6. It is particularly suitable for:
- Patients with needle phobia who cannot tolerate multiple tumescent injections
- Patients requiring bilateral treatment in a single session
- Physicians seeking an outpatient, office-based solution with minimal downtime
Clinical Evidence
VenaBlock® has been evaluated in multiple international clinical studies. The RIVIERA trial (Singapore) demonstrated high technical success and safety at 6-month follow-up. Long-term data shows a 12-month closure rate of 93.75% and a 12-month closure rate of 93.75% (long-term follow-up ongoing), confirming durable efficacy comparable to thermal ablation methods.
Conclusion
VenaBlock® represents a significant advancement in minimally invasive vein care. By combining the proven efficacy of endovenous closure with a non-thermal mechanism, it delivers excellent patient outcomes while substantially reducing procedural complexity and post-operative discomfort. For physicians and patients seeking a modern, evidence-based approach to varicose vein treatment, VenaBlock® is a compelling choice.